Orbital™ DPI: High-Payload Pulmonary Drug Delivery Platform

Why High-Payload Pulmonary Delivery Is Becoming Increasingly Important

Pulmonary drug development is evolving rapidly, driven by the need to deliver more complex therapies and larger quantities of active pharmaceutical ingredients directly to the lungs. In therapeutic areas such as cystic fibrosis, bronchiectasis, pulmonary infections and inhaled oncology, achieving the desired therapeutic effect may require payloads beyond the range traditionally associated with many dry powder inhalers. As dose requirements increase, developers are reassessing whether existing inhalation platforms can maintain consistent delivery performance while still supporting a manageable patient experience. Conventional DPI formats remain effective for many applications, but higher payloads can expose limitations related to inspiratory effort, device handling and administration burden.

A Key Question for Emerging Inhaled Therapies: What makes high-payload pulmonary delivery challenging?

As inhaled therapies become more complex, the challenge is not only to deliver larger quantities of powder to the lungs, but to do so consistently, comfortably and in a way that patients can manage in real-world use. Conventional DPI formats may become less practical when dose requirements increase, particularly if they rely on single-breath delivery, repeated loading steps or inspiratory effort that may be difficult for patients with compromised lung function. Orbital™ addresses this challenge through a progressive multi-breath delivery approach designed to support high-payload administration while keeping usability and system-level performance at the centre of the inhalation process.

Beyond Powder Delivery: A System-Level Challenge

As therapies become more demanding, successful pulmonary delivery increasingly depends on the interaction between formulation behaviour, device performance and patient use throughout the full dosing process. High-payload delivery must therefore be evaluated as a system rather than as a single inhalation event. Relevant considerations include how consistently the formulation disperses, how reproducibly the dose is transferred across successive breaths and how device behaviour interacts with patient handling under realistic conditions. This broader perspective has led to growing interest in inhalation platforms designed specifically to address both the technical and practical complexities associated with higher-payload therapies.

A Different Approach to High-Payload Delivery

Aptar Pharma’s Orbital™ Dry Powder Inhaler platform was developed in response to these evolving needs. Designed to support pulmonary delivery of high-dose formulations, typically in the range of 100 to 400 mg or more, the platform offers a different approach to dose administration. Rather than relying on a single, forceful inhalation to deliver a large powder bolus, Orbital™ uses a progressive multi-breath delivery mechanism that distributes the dose across several gentle inhalations. This approach can help reduce dependence on peak inspiratory effort and make the administration sequence easier for patients to manage. By avoiding the delivery of a large powder mass in one inhalation event, progressive aerosolization may also support a more patient-adapted delivery experience.

Rethinking DPI Architecture for Complex Therapies

The Orbital™ platform combines progressive powder dispersion with low inhalation resistance and flexible configuration options, including single-use and reloadable formats. This architecture reflects a shift away from the traditional single-breath DPI paradigm toward a more controlled and patient-adapted delivery process. Compared with conventional systems that may require repeated capsule loading or place greater reliance on inspiratory effort, Orbital™ is designed to support high-payload delivery while simplifying administration. This distinction becomes increasingly important as developers seek inhalation solutions capable of balancing performance requirements with usability considerations across a broad range of complex therapy programs.

Supporting Development Through an Integrated Approach

Achieving successful pulmonary delivery at high payloads requires more than device technology alone. Formulation characteristics, inhalation performance, and patient interaction must be considered together throughout development. Aptar Pharma positions Orbital™ within a broader development ecosystem that combines formulation expertise, inhalation performance characterization and human factors engineering. This integrated approach helps align delivery performance with formulation requirements and intended patient use from early development through commercialization. By addressing these elements in parallel rather than sequentially, developers can gain a more complete understanding of delivery behaviour and reduce potential late-stage development risk.

Looking Ahead

As pulmonary therapies continue to evolve, the demands placed on inhalation platforms are expected to increase. High-payload capability, usability, and development flexibility are becoming central considerations for drug developers working on complex and high-value therapies. Through its combination of progressive multi-breath delivery, high-payload capacity and system-level development support, the Orbital™ DPI platform reflects a broader move toward inhalation solutions designed not only to deliver medicine effectively, but also to address the practical realities of patient use and product development in an increasingly sophisticated respiratory therapy landscape.